FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 288 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 Girls Aloud members to join forces to raise money in Sarah... June 14, 2022 Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ January 6, 2020 Load more HOT NEWS NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom... Wales: 4 in 10 with possible cancer symptoms didn’t contact GP EMA Recommends Extension of Indications for Selumetinib
